GlassScriptPhysician profile
Thomas P Heffernan
NPI 1326148651
$95,381.17
in general payments reported to CMS, 2019-2025
34 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $8,988 · 2021: $4,181 · 2022: $11K · 2023: $15K · 2024: $15K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $15K · Food and Beverage: $3,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,512.50 |
| Travel and Lodging | $14,538.63 |
| Food and Beverage | $3,435.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Momentis Surgical INC. | $52,902.97 | 2022-2025 | Anovo Surgical System, Anova Surgical System |
| Intuitive Surgical, INC. | $24,148.23 | 2019-2025 | Da Vinci Surgical System |
| Clovis Oncology, INC. | $11,986.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,250.20 | 2019-2025 | Lynparza |
| Daiichi Sankyo INC. | $728.57 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $445.58 | 2019-2025 | Keytruda, Lenvima |
| Genmab U.S., INC. | $388.02 | 2021-2025 | Tivdak |
| Glaxosmithkline, LLC. | $321.39 | 2019-2025 | Zejula, Jemperli |
| Abbvie INC. | $257.89 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $244.52 | 2022-2023 | Precisetumor |
| Coherus Oncology, INC. | $214.63 | 2020-2022 | |
| Tesaro, INC. | $213.85 | 2019 | |
| Spectrum Pharmaceuticals INC. | $207.11 | 2024-2025 | Rolvedon |
| Seagen INC. | $120.64 | 2022 | |
| Immunogen, INC. | $110.81 | 2024 | Elahere |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $100.06 | 2020 | |
| Baxter Healthcare | $92.41 | 2023-2025 | Perclot, Tisseel |
| Genentech USA, INC. | $72.29 | 2019 | |
| Amgen INC. | $63.79 | 2019-2020 | |
| Conmed Corporation | $57.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $54.78 | 2024 | |
| Janssen Biotech, INC. | $50.33 | 2025 | Darzalex, Tecvayli, Talvey |
| Biom'Up France Sas | $44.52 | 2020 | |
| Tersera Therapeutics LLC | $43.02 | 2019-2025 | Quzyttir |
| Astellas Pharma US INC | $41.85 | 2024 | Padcev, Veozah |
| Pharmaand Gmbh | $39.84 | 2025 | Rubraca |
| Jazz Pharmaceuticals INC. | $29.12 | 2024 | |
| On Target Laboratories, INC | $28.42 | 2025 | Cytalux |
| Sobi, INC | $27.33 | 2025 | |
| Eisai INC. | $25.48 | 2025 | |
| Stemline Therapeutics INC. | $18.87 | 2024 | Orserdu |
| American Regent | $18.34 | 2025 | Injectafer |
| Taiho Oncology, INC. | $17.83 | 2022 | |
| Therapeuticsmd, INC. | $14.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Heffernan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.